What Dexcom's 8-K filings say: 5 filings, latest Sep 14, 2026
Dexcom filed its latest 8-K with the SEC on Sep 14, 2026. It discusses COO change, governance change and restructuring.
Public (DXCM)Medical Equipment Manufacturing10,000+ employeesdexcom.comLinkedIn
- Filed
- Sep 14, 2026
- Filings
- 5
- Signals
- 14
8-K · latest 6
What Dexcom's 8-K filings say
- SEC EDGAR
8-K
Filed · 3 signals
DexCom promotes CFO Jereme Sylvain to dual CFO/COO role, effective Sept 14, 2026
The promotion of the CFO to a combined Chief Operating and Financial Officer role centralizes operational and financial oversight under one executive.
$0.8M
New annual base salary for Jereme Sylvain, the new COO and CFO.
75%
Annual target bonus opportunity as a percentage of base salary for the new COO and CFO.
- SEC EDGAR
8-K
Filed · 3 signals
DexCom appoints Glenn S. Boehnlein to Board and key committees, effective immediately
The immediate appointment of a new director to the Operations & Innovation and Audit committees signals a potential shift in strategy and oversight.
$0.5M
Initial RSU equity grant for new board member
- SEC EDGAR
8-K
Filed · 2 signals
Dexcom targets 10%+ annual revenue growth through 2030, signaling major strategic investments.
The company announced aggressive long-range financial targets, including sustained 10%+ annual revenue growth and an operating margin of 29-30% by 2030.
10%
Minimum annual organic revenue growth target through 2030
- SEC EDGAR
8-K
Filed · 4 signals
Kevin Sayer has returned from a temporary leave of absence to resume his role as Executive Chairman, providing ongoing leadership and strategic guidance.
$2.4M
Fair value of restricted stock units granted to returning Executive Chairman Kevin R. Sayer.
The company entered a new letter agreement with its returning Executive Chairman, providing a $610,000 annual salary and $2.35 million in restricted stock units.
$3M
Total compensation package (salary + RSUs) for Executive Chairman Kevin Sayer.
- SEC EDGAR
8-K
Filed · 2 signals
DexCom appoints Albert F. Osterloh to Board of Directors and Technology Committee
The appointment of a new director, Albert F.
$0.5M
Initial appointment equity grant of restricted stock units (RSUs) for new director
Showing 6 of 14 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Dexcom with the Signal API
One POST /v1/companies/enrich call with dexcom.com returns Dexcom 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"dexcom.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about Dexcom 8-K
When did Dexcom file its latest 8-K?
What did Dexcom disclose in its latest 8-K?
Where can I read Dexcom's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .